1 citations
,
January 2025 in “JEADV Clinical Practice”
This study reported that the AAPPO tool effectively distinguishes between patients with alopecia areata based on scalp hair loss severity, whereas the EQ‐5D‐5L may underestimate the specific disease burden, particularly in psychological and social aspects.
January 2026 in “Journal of Cutaneous Immunology and Allergy”
In this case report, a young Japanese man was diagnosed with scalp IgG4-relateddisease, which mimicked acne keloidalis nuchae but was identified by histopathology and elevated serum IgG4 levels as a systemic fibroinflammatory disorder, highlighting the importance of differential diagnosis in atypical scarring alopecia.
1 citations
,
June 2020 in “British Journal of Dermatology”
This article reviews the psychological impact of alopecia areata on patients, including lower self-esteem and poorer quality of life, and reports no new clinical results.
This study observed that COVID-19-related stress and fear were potentially associated with an increased occurrence of hair diseases like telogen effluvium, alopecia areata, and seborrheic dermatitis among medical students in Bangladesh.
The conversation is about finding a solution for scalp inflammation related to AGA, with the user expressing frustration that Minoxidil and Finasteride do not address inflammation. The user has researched glucocorticoids and topical NSAIDs for reducing inflammation and seeks advice from specialists.
Vitamin E and K deficiencies due to exocrine pancreatic insufficiency may affect hair growth. A scalp biopsy is recommended to check for autoimmune-related hair loss.
A 20-year-old male has been experiencing hair loss since age 15-16 and is using oral minoxidil, dutasteride, and ketoconazole shampoo, with previous use of oral finasteride and topical minoxidil. He has stabilized hair loss but seeks to rule out inflammatory or immune-related causes, considering a scalp biopsy, and is supplementing with vitamin D3, B12, and iron.
Dihydrotestosterone (DHT) impacts various skin conditions, including Androgenetic alopecia and seborrheic dermatitis, by causing overactivity in sebaceous glands. Topical medications Tacrolimus and Clobetasol can reduce these inflammatory conditions, and treatments like RU58841, Minoxidil, and Finasteride may also be beneficial.
Increased Malassezia and Cutibacterium in the scalp microbiome are linked to higher sebum production and inflammation in androgenetic alopecia (AGA). Treatments include ciclopirox shampoo, benzoyl peroxide shampoo, clobetasol propionate, calcipotriol, minoxidil, finasteride, and dutasteride.